MONTREAL, CANADA–(Marketwired – May 22, 2013) – Technologies -Scan Corp (TENP) announces that it is presently negotiating with Social Media Geek for an option on the acquisition of an exclusive license of its Proteina21 Weight loss product line for the Canadian market. The company is already in a due diligence phase with Social Geek Media for the exclusive sales, marketing and commercialization of the Proteina21 weight loss product line for the USA. Ghislaine St-Hilaire CEO of Technologies-Scan Corp says that she is ” thrilled at the developments concerning the company’s relationship with Social Geek Media and the Proteina21 product line, we see a bigger synergy for our companies than just the US market and that is why we are in discussions concerning the Canadian market which Proteina21 has had sales of over 500 000 in the first quarter.”

Proteina21 is a product line of food supplements and readymade meals high in protein and low in carbohydrates designed to help people lose weight. The products are shipped overnight and are available through internet sales on their website at http://www.proteina21.com

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements which address actual results could differ materially from those expressed or implied in forward-looking statements. These statements are made on the basis of management’s views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that the ability to attract clients and generate business may be affected by a decline in the Company’s financial ratings, the competitive environment, the Company’s ability to raise sufficient capital to meet the collateral requirements associated with its current business and to fund the Company’s continuing operations and changes in market conditions.

LAWRENCEVILLE, N.J., May 17, 2013 /PRNewswire/ — Celsion Corporation (CLSN) announced today that Professor Riccardo Lencioni, MD, FSIR, EBIR, 2013 WCIO Program Chairman and the Director of the Division of Diagnostic Imaging and Intervention at Pisa University School of Medicine in Italy and Lead European Principal Investigator for the HEAT Study and Professor Ronnie T.P. Poon, MD, MS, PhD, FRCS(Edin), FACS, Professor of Surgery at the University of Hong Kong and Lead Asia Pacific Principal Investigator for the HEAT Study conducted separate scientific discussions reviewing the clinical trial results from the Company’s Phase III HEAT Study including new emerging findings from the HEAT Study post-hoc analysis at the 9th Annual Meeting of the World Conference on Interventional Oncology, which is being held on May 16 to 20, 2013 in New York City. The new post-hoc findings suggest that optimized heating cycles markedly improve radiofrequency ablation (RFA) plus ThermoDox’s potential for clinically relevant improved progression free survival (PFS) and Overall Survival (OS) outcomes. Professors Poon and Lencioni both concluded that the findings warrant further investigation and development of ThermoDox as a first line treatment for HCC when combined with RFA. The slide presentations are available on the Events and Presentations page on the Celsion website.

“I was pleased to discuss this post-hoc analysis of a large subgroup of patients from the Phase III HEAT Study at the WCIO Conference in New York which may be indicating a meaningful clinical benefit in both PFS and Overall Survival in patients who received an optimized RFA procedure,” said Professor Lencioni. “It would appear that the duration of heat from the RFA procedure is a key factor in a successful clinical outcome when combined with ThermoDox as suggested by this analysis. These findings may offer a path forward to potentially offering an important new therapy for HCC patients with limited treatment options.”

“This subgroup analysis of approximately 300 patients, although not statistically significant, is nevertheless demonstrating a strong positive trend in both PFS and Overall Survival in ThermoDox® treated patients when heating cycles from the RFA procedure were optimized,” said Professor Ronnie Poon. “What we have learned from the HEAT Study is that there is a large cohort of patients that appear to have demonstrated an important benefit from ThermoDox provided the RFA treatment time is properly applied. These findings are quite encouraging and should be confirmed with additional non-clinical studies and clinical trial data.”

The data from the HEAT Study post-hoc analysis presented by Professors Lencioni and Poon demonstrate that ThermoDox markedly improves PFS and OS in patients with a single lesion if their lesions undergo RFA for 45 minutes or more. These findings apply to HCC lesion regardless of size and represent a subgroup of approximately 300 patients or 42% of the patients in the HEAT Study. The post-hoc analysis completed by the Company to-date indicates that there may be a large patient cohort that benefited from RFA plus ThermoDox regardless of lesion size.
•In the patient subgroup treated in the ThermoDox arm whose RFA procedure lasted longer than 45 minutes and was completed within 90 minutes (40% of single lesion patients), Overall Survival improved by 66% (Hazard Ratio of 0.602) when compared to the control arm of RFA treatment only.
•In the patient subgroup treated in the ThermoDox arm whose RFA procedure lasted longer than 90 minutes (23% of single lesion patients), Overall Survival almost doubled (Hazard Ratio of 0.508) when compared to the control arm of RFA treatment only.
•When combined, these two subgroups show clinical results that indicated a 53% improvement in Overall Survival, a Hazard Ratio of 0.65, and a Pvalue = 0.105.
•In contrast, the patient subgroup treated with ThermoDox whose RFA procedure lasted less than 45 minutes in duration (37% of single lesion patients) indicated that the control arm had an improved Overall Survival benefit when compared to the ThermoDox arm.
•The Hazard Ratios reported above should be viewed with caution since they are not statistically significant and the HEAT Study has not reached its median point for Overall Survival analysis. Celsion will continue following all patients enrolled in the HEAT Study to the secondary endpoint, Overall Survival, and update its subgroup analysis based on RFA heating duration.

Dr. Lencioni’s presentation, titled “Advances in Image-Guided Ablation” was held in Plenary Session: Multidisciplinary State-of-the Art: HCC and Professor Poon’s presentation, titled “Thermally Sensitive Drug Carriers” was held in Concurrent Session: New Drugs/New Carriers/New Devices. Both presentations were held on Thursday, May 16, 2013 and are available on the Company’s website at http://www.celsion.com under “News & Investor Info – Events & Presentations.”

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license or commercialization agreements with leading institutions, including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford. For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of conducting clinical trials; HEAT Study data is subject to further verification and review by the HEAT Study Data Management Committee; the need for Celsion to evaluate its future development plans; termination of the Technology Development Contract or collaboration between Celsion and HISUN at any time; possible acquisitions or licenses of other technologies, assets or businesses or the possible failure to make such acquisitions or licenses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion ‘s periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact
Jeffrey W. Church
Sr. Vice President — Corporate
Strategy and Investor Relations
609-482-2455
jchurch@celsion.com

CARSON CITY, Nev., May 2, 2013 /PRNewswire/ — Xumanii™ (the “Company”) (XUII), a company that has developed proprietary technology capable of broadcasting live events in HD wirelessly from multiple cameras at events for an extremely low production cost, announces today that the Company has acquired the master license to a cutting-edge IP portfolio that will significantly enhance the Company’s current platform technology. The Master License agreement allows Xumanii access to technology that can significantly enhance the bitrate at which video is uploaded and broadcast through its platform. “The rapidly expanding, multi billion dollar live stream market is highly competitive and technologically advanced so acquiring this intellectual property was key to maintaining and boosting our edge over the competition,” said company President Alex Frigon. He went on to say that, “The average American family watches over 5 hours a day of video content. Currently, the online video market is a one-way push model that is grossly inefficient. We believe that we can combine streaming video and e-commerce on our platform by introducing products that accompany content. Adding to that fact is that our platform can be viewed globally so our reach can be enhanced by a huge multiplier.” The XUMANII team and I look forward to announcing the upcoming lineup of talent that will be able to be viewed “live’ on our platform. Please log in regularly or sign up on our website at http://www.xumanii.com to receive notices of upcoming live events.

About XUMANII™

Xumanii™ is an all-inclusive online platform that provides users the opportunity to create a “Live Broadcast” in true High Definition. Xumanii™’s new, patent pending technology integrates proprietary hardware and software wirelessly, streaming live feeds from multiple cameras in High Definition Audio/Visual with capabilities of up to 10 Megabites per seconds. This technology integrated Hardware and Software allows for the highest quality “live broadcast” without the exorbitant expenditure of traditional methods currently used in the marketplace via the respective Artist’s Channel on Xumanii.com. The Company’s technology can also be provided to each Artist allowing them to broadcast any event in which they feel that they would like their fans to be a part of.

Safe Harbor Statement
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The company cautions that these forward-looking statements are further qualified by other factors. The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.

XUII Investor Relations
Maplehurst
Tel: 917.838.3991

Leveraging its proprietary technology and multi-year partnership with Realtor.com, RealBiz Media provides the premier multi-faceted video creation and delivery platform for the real estate market. Consumers and agents can access and interact with the content via the Web, mobile devices or through the Company’s video on-demand television network currently available in key U.S. markets.

In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines his investment thesis.

“The real estate market has enjoyed a tremendous resurgence in recent months. Interestingly, one of the drivers of the current and future market is the use of technology and digital media as a primary tool to provide information and help execute transactions. With $30M invested in its proprietary technology, and 30,000 agents already using the Company’s services, we envision additional market penetration through the Realtor.com network and its television network. As utilization of the Company’s offerings deepen, financial leverage and monetization should foster meaningful top-line growth.”

To view a summary of the report or download the report in its entirety, please visit
http://www.goldmanresearch.com

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit http://www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report’s full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit http://www.goldmanresearch.com.

About RealBiz Media Group Inc. (OTCQB: RBIZ): RealBiz Media Group, Inc. is a real estate media services company whose proprietary video processing technology has made it one of the leaders in providing home virtual tours to the real estate industry. Its client base includes more than 60,000 real estate agents and brokers. Through its wholly owned Home Tour Network, the company also includes a television video on demand network. RealBiz enjoys access to the nation’s largest real estate companies with numerous approved vendors and national contracts, both key to its future development programs. When completed, the Company is targeting delivery of its multimedia Video on Demand platforms to more than 70 million households along with a supporting web portal and an agent-driven Micro Video App program.

For more information, visit the Company’s website: http://www.realbizmedia.com.
.
.
Contact:.
.
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com

The realtor.com® channel in Atlanta has the potential to connect hundreds of thousands of interested home buyers, sellers, and curious home viewers to agents and available listings in their local market. “We are very excited to see the realtor.com® channel off to such a quick start in the video on demand space,” said Steve Marques, President/CRO for Realbiz Media. “Our service agreement with realtor.com® is moving along well. We are looking forward to getting Atlanta off to a quick start and to continuing the expansion of the network and the realtor.com® channel. We are also very pleased with the support and advanced interactive technologies offered by Comcast® in Atlanta and are confident that their system will help drive additional traffic to our network.” Click here to see an example of an interactive TV ad spot for the realtor.com® channel.

About RealBiz Media Group, Inc.

RealBiz Media Group, Inc. (OTCQB: RBIZ) is a real estate media services company whose proprietary video processing technology has made it one of the leaders in providing home virtual tours to the real estate industry. Its client base includes more than 60,000 real estate agents and brokers. Through its wholly owned Home Tour Network, the company also includes a television video on demand network. The company enjoys access to the nation’s largest real estate companies with numerous approved vendors and national contracts, both key to its future development programs. When completed, the company is targeting delivery of its multimedia Video on Demand platforms to more than 70 million households along with a supporting web portal and an agent-driven Micro Video App program. For more information, visit our website at http://www.realbizmedia.com.

Safe Harbor Statement

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plan, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks described in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements that may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
.
.
Contact:.
.
CONTACT:
RealBiz Media Group, Inc.
Direct: (954) 888-9779
investorrelations@realbizmedia.com
.

Chris Trina, Chairman and CEO of ESI stated this, “This is extremely exciting and encouraging for both companies. After almost 3 weeks of performing due diligence since the April 16th announcement of our letter of intent to acquire ASG much has been accomplished. Our team literally spent hours and hours sitting with the owners in their office going over their current financials and their expected future goals. Performing proper due diligence requires more than receiving bank statements and pro-formas,” Trina stated. “To really understand and learn about a potential subsidiary candidate our team must be face-to-face with them often, having lunch and dinner, meeting wives or husbands and their family members, speaking to vendors and employees alike and looking over major contracts. We must become part of their family so to speak over a very short period of time to obtain that “warm and fuzzy” one must feel to partner up with a company” Trina explained. Trina further stated, “I think the most difficult task after the due diligence process is completed is agreeing on the valuation of the target company. All three partners of ASG unanimously voted in favor of our initial valuation which opened the door to completing our first acquisition at ESI which super exciting for our shareholder’s.” Trina ended by saying, “There is indeed more work to be done and some very important items to be further discussed to finalize this transaction; however the excitement level from both sides and the progress already made makes me believe we can wrap this up by late May.”

Troy Tipton, Vice President of Operations at Air Systems Group quoted, “we are very excited to move forward with ESI in becoming a wholly owned subsidiary. The benefits of being part of a publicly traded entity are exciting at many levels.”

About ESI
Enviro-Serv Inc. (EVSV) is a Tampa based corporation specializing in providing property maintenance services in geographically concentrated warm climate states. Through an aggressive acquisition strategy, the Company is building a portfolio of highly profitable enterprises that offer year round services such as pest control management, lawn and landscaping care, pool maintenance, air conditioning/refrigeration installation and repairs and a host of additional onsite maintenance offerings. Please visit their website at http://www.enviro-serv.com

About ASG
Air Systems Group (ASG) specializes in commercial refrigeration and air conditioning, providing superior customer achievements for all project sizes and needs. The company’s installations, along with the scores of services provided have positioned ASG as a leading and inclusive contractor for today’s construction projects. A testimony to their quality services can be seen in their client list which includes Circle K and Sunoco establishments. In addition to commercial Stores, ASG services restaurants, car dealerships, schools, strip centers, assisted living facilities, hotels, along with an assortment of commercial and residential applications. In addition to their service department, ASG directs a full commercial division that is responsible for the installation of ductwork, refrigeration coolers, kitchen hoods, ventilation and other related aspects of commercial and residential construction. Please visit their website at http://www.airsystemsservices.com

Forward-Looking Statements – This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Enviro-Serv Inc. undertakes no obligation to update such statements.

CONTACT:

Enviro-Serv Inc. – 813-975-7177
.

VANCOUVER, BRITISH COLUMBIA–(Marketwired – April 30, 2013) – Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) (“Calyx” or the “Company”) is pleased to provide an update on the Resonance® carinata growing program currently being conducted by its majority-owned subsidiary, Agrisoma Biosciences Inc. (“Agrisoma”).

The 2013 growing program was introduced on March 26, 2013, at a day-long event held in Swift Current, Saskatchewan, in connection with the Government of Saskatchewan’s Ministry of Agriculture, the Saskatchewan Mustard Development Commission, and Prairie Gold. The presentation covered a range of topics of interest to potential growers, including agronomics, Resonance® carinata breeding and varieties, crop inputs (fertilizer, weed & insect control), crop insurance, and grower experiences from last year.

The 2013 contracting program is in progress. Spring has been colder and longer than normal this year. Farmers in Alberta, Saskatchewan and Manitoba usually begin planting in late April in southern areas, but 2013 planting has been delayed for many growers. The delayed planting season and resulting shortened growing season is not expected to impact the ability of growers to successfully cultivate Resonance® carinata in the current year. A further update will be provided when the growing season progresses.

About Calyx

Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) is an agricultural technology company focused on renewable fuels including biojet and biodiesel. Calyx’s majority-owned operating subsidiary, Agrisoma Biosciences Inc., is producing a new proprietary non-food energy feedstock crop, Resonance® carinata, which yields oil that can be refined into fuels that work in existing engines as a 100 percent petroleum substitute. From seed to sky, fuels produced from Resonance® carinata substantially reduce carbon and other harmful emissions, and help to reduce global petroleum dependence. For further information about Calyx, please visit http://www.calyxbio.com.

Forward-Looking Statements: This document contains certain forward-looking statements concerning Calyx and/or Agrisoma, as well as other expectations, plans, goals, objectives, information or statements about future events, conditions, results of operations or performance that may constitute “forward-looking statements” or “forward-looking information” under applicable securities legislation. Such statements or information involve substantial known and unknown risks and uncertainties, certain of which are beyond Calyx’s and/or Agrisoma’s control, including general business, economic, competitive, political and social uncertainties; the delay or failure to receive regulatory approvals, the characteristics and viability for bio-fuel development, the willingness of third parties to conclude agreements with Calyx and/or Agrisoma on terms that are acceptable to management of Calyx and/or Agrisoma, and the ability of Calyx and/or Agrisoma to secure sufficient future funding to carry out all of its business plans.

Such forward-looking statements or information are based on a number of assumptions, which may prove to be incorrect. In addition to other assumptions identified in this news release, assumptions have been made regarding, among other things, commodity prices, operating conditions, capital and other expenditures, and project development activities.

Although Calyx and/or Agrisoma believes that the expectations reflected in such forward-looking statements or information are reasonable, undue reliance should not be placed on forward-looking statements because Calyx and/or Agrisoma can give no assurance that such expectations will prove to be correct. Forward-looking statements or information are based on current expectations, estimates and projections that involve a number of risks and uncertainties which could cause actual results to differ materially from those anticipated by Calyx and/or Agrisoma and described in the forward-looking statements or information.

The forward-looking statements or information contained in this news release are made as of the date hereof and Calyx and/or Agrisoma undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise unless so required by applicable securities laws or the TSX Venture Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

This press release shall not constitute an offer to sell, nor the solicitation of an offer to buy, any securities in the United States, nor shall there be any sale of securities mentioned in this press release in any state in the United States in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:
Calyx Bio-Ventures Inc.
W. Hugh Notman
President & CEO
604-689-2495
hnotman@calyxbio.com

SAINT LAURENT, Quebec, April 24, 2013 (GLOBE NEWSWIRE) — Horst Zerbe, President and CEO of IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx” or the “Company”) today announced that Rajiv Khosla RPh, PhD, MBA has been appointed Chief Operating Officer and Chief Scientific Officer of the Company, effective immediately. Dr. Khosla has been a member of the Company’s board of directors for the past two years and, in accordance with the employment agreement, has now relinquished his board position.

“I am elated that Dr. Khosla has agreed to bring his outstanding leadership abilities and vision to IntelGenx on a full-time basis,” Dr. Zerbe said, adding that the appointment is key to the Company’s strategic plan for smooth succession, continuity and growth.

“We have secured the right leadership for the future,” Dr. Zerbe said. “Rajiv has a record of success in business development and in leading growth in our sector. Those are essential attributes as IntelGenx moves forward.”

Dr. Zerbe also noted that Dr. Khosla has deep knowledge in drug delivery systems. He is the first COO at IntelGenx. The succession plan will see Dr. Khosla become CEO and President of IntelGenx on January 1, 2014 and for Dr. Zerbe, who built the Company from the ground up, to remain as Chairman of the board of directors and continue to provide expertise in research and development, and manufacturing.

Since the beginning of this year, Dr. Khosla has been a consulting member of the IntelGenx management team, assisting with strategic operations, business development activities and advising on current and future pharmaceutical project development.

IntelGenx, a Canadian company, develops drug delivery systems that solve challenges encountered in oral drug delivery, with technologies that improve the performance of a wide variety of pharmaceutical compounds. IntelGenx has developed capacities to tailor drug release profiles and target specific absorption sites to unlock the full therapeutic potential of a drug. It recently submitted a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for its anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm™ technology

Dr. Khosla has remarkable experience and credentials including, among other senior positions, five years as Vice President of Business Development at Biovail Corporation, a Canadian pharmaceutical company operating internationally. Whilst there, Dr. Khosla successfully led the transaction process for more than 75 deal opportunities in a variety of therapeutic areas.

He holds a Ph.D. in pharmaceutical science, with a thesis on Oral Drug Delivery Technology; an Executive MBA from the Henley Business School in England, a Bachelor of Pharmacy (Honours) from the University of Nottingham, England and is a registered pharmacist in the UK.

About IntelGenx:

IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx’ development pipeline includes products for the treatment of severe depression, hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, idiopathic pulmonary fibrosis, allergies and pain management. More information is available about the company at http://www.intelgenx.com.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx’ operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx’ plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words “may,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “could,” “would,” and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx’ actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading “Risk Factors” in IntelGenx’ annual report on Form 10-K for the fiscal year ended December 31, 2012, filed with the United States Securities and Exchange Commission and available at http://www.sec.gov, and also filed with Canadian securities regulatory authorities and http://www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements

VANCOUVER, BRITISH COLUMBIA–(Marketwired – April 23, 2013) – Canamex Resources Corp. (TSX VENTURE:CSQ)(OTCQX:CNMXF)(FRANKFURT:CX6) is very pleased to announce the assay results of the first and second drill holes of the 2013 drilling program at the Penelas East target area on the Bruner Gold Project, Nye, County, Nevada.

Drill hole B-1301 intersected 91.4 meters of 3.1 gpt (300 feet grading 0.090 opt) Au between 290-590 feet, including 5 feet grading 117 gpt (3.402 opt) Au and 396 gpt (11.55 opt) silver between 415-420 feet, in what is believed to be the second best intercept ever drilled on the Bruner property. The intercept in drill hole B-1301 is located approximately 55 meters (180 feet) south of the discovery hole B-1201 reported last year which contained 110 meters of 4.08 gpt (360 feet grading 0.119 opt) Au between 290-650 feet. In addition, drill hole B-1301 intersected two thinner and lower grade zones further down the hole at 660-695 feet grading 1.507 gpt (0.044 opt) Au and 750-780 feet grading 0.474 gpt (0.014 opt) Au.

Drill holes B-1301 and B-1201 are very similar in character with a high-grade core almost centered on an extensive and robust lower grade halo surrounding the high-grade core. Importantly, drill hole B-1301 is on the southern end of the drilling pattern completed to date at the Penelas East target area, and the wide zone of mineralization with a central high-grade core remains open to the south. Mineralization at this depth could be accessible by open pit.

Drill hole B-1302 (N95E azimuth and -75 degree inclination) was designed to intersect the mineralized zone 60 meters (200 feet) below that in B-1301 (N95E azimuth and -60 degree inclination) and intersected 16.8 meters (55 feet) grading 1.563 gpt (0.046 opt) Au from 640-695 feet. At this point we do not know if this intercept is the down-dip equivalent of the thicker high-grade zone encountered in B-1301 or whether the target dips to the east and thus out of reach of drill hole B-1302.

The mineralized zone appears to be steeply dipping but of unknown true width. The drill intercepts are summarized in the following table, and the complete table of results appears at the end of this release.

Highlights of Drill Hole B-1301

Hole

From (ft)

To (ft)

Thickness (ft)

Au grade g/tonne

Au grade oz/ton

B-1301

290

590

300

3.10

0.090

including:

415

420

5

117.00

3.402

All intercepts greater than 3 gpt (0.09 opt) Au are being re-assayed from a 1 kilogram split from the coarse rejects and pulverized entirely to -200 mesh to assess the presence of particulate gold in the higher grade intercepts.

12 Hole 2013 Spring Drilling Program at Penelas East

A total of twelve holes are planned for the Penelas East target area in the first half of 2013 to obtain a better understanding of the geometry and orientation of the mineralized zone, which is not exposed at the surface, being beneath 30 feet of alluvial cover and several hundred feet of mostly unmineralized flow-banded rhyolite, the latter of which appears to have formed an effective cap on the hydrothermal system. Results from these holes will be announced as they are received and analyzed and are expected to be released on a section-by-section basis going forward.

Quality Control

Drill samples were stored in a locked storage unit and retrieved by ALS-Chemex personnel, transported in their custody to the ALS-Chemex laboratory in Reno/Sparks, Nevada, where they were dried, crushed, and split, and representative splits sent to the ALS-Chemex laboratory in Vancouver for gold and silver analyses. Duplicates, blanks, and standards were inserted at regular intervals for QA/QC purposes.

Greg Hahn, Certified Professional Geologist (#7122) is the Qualified Person who has prepared and reviewed this press release in accordance with NI 43-101 reporting standards.

ON BEHALF OF THE BOARD

Robert Kramer, Chairman and CEO

Forward-Looking Statements:

This news release includes certain forward-looking statements or information. All statements other than statements of historical fact included in this release are forward-looking statements that involve various risks and uncertainties. Forward-looking statements in this news release include statements with respect to the estimated costs and timing of drilling programs on the Bruner property, the potential mineralization and geological merits of the Bruner property, and other future plans, objectives or expectations of the Company. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s plans or expectations include the risk that actual results of current and planned exploration activities, including the results of the Company’s planned 2013 drilling program(s) on the Bruner property, will not be consistent with the Company’s expectations; the geology, grade and continuity of any mineral deposits and the risk of unexpected variations in mineral resources, grade and/or recovery rates; fluctuating metals prices; possibility of accidents, equipment breakdowns and delays during exploration; exploration cost overruns or unanticipated costs and expenses; uncertainties involved in the interpretation of drilling results and geological tests; availability of capital and financing required to continue the Company’s future exploration programs and preparation of geological reports and studies; delays in the preparation of geological reports and studies; the metallurgical characteristics of mineralization contained within the Bruner property are yet to be fully determined; general economic, market or business conditions; competition and loss of key employees; regulatory changes and restrictions including in relation to required permits for exploration activities (including drilling permits) and environmental liability; timeliness of government or regulatory approvals; and other risks detailed herein and from time to time in the filings made by the Company with securities regulators.

GENETIC-AF is planned as a Phase 2b/3 clinical trial comparing Gencaro to metoprolol CR/XL for prevention of atrial fibrillation (“AF”) in patients with heart failure and reduced left ventricular ejection fraction (“HFREF”). ARCA plans to enroll only patients with the genetic variant of the beta-1 cardiac receptor which the Company believes responds most favorably to Gencaro. GENETIC-AF has an adaptive design, under which the Company plans to initiate it as a Phase 2b study in approximately 200 patients and then, depending on the results of an interim analysis, expand the trial to a Phase 3 study by enrolling an estimated additional 420 patients.

Under the collaboration, ARCA plans, with the support of Medtronic, to conduct a substudy that will include continuous monitoring of the cardiac rhythms of all 200 patients enrolled during the Phase 2b portion of GENETIC-AF. Each patient will have heart rhythm monitoring via a Medtronic device, either a previously implanted cardiac resynchronization or defibrillation device, or a previously or newly inserted Reveal® loop recorder. The collaboration substudy will measure AF burden, defined as a patient’s actual time in AF regardless of symptoms. In determining the presence of an efficacy signal in the Phase 2b portion of the trial, AF burden will be evaluated along with time to mortality or recurrent AF, which will also be the Phase 3 primary endpoint.

ARCA believes that the AF burden endpoint will help provide an accurate and comprehensive assessment of each patient’s AF episodes, and will be useful in evaluating the relative efficacies of Gencaro and metoprolol CR/XL. Under the collaboration, Medtronic will support the implantation and use of the Medtronic monitoring devices, and will manage the AF burden data collection and analysis. If GENETIC-AF proceeds to Phase 3, the parties will seek to enroll at least 100 additional patients in the AF burden substudy.

Dr. Michael Bristow, MD, PhD, President and Chief Executive Officer of ARCA, said, “We are excited about our collaboration with Medtronic on GENETIC-AF. We believe that the use of implanted, continuous monitoring devices that allow for the more precise measurement of atrial fibrillation represents the next generation of diagnosis and treatment options for patients at risk for this disease. The GENETIC-AF trial has the potential to result in an approvable new therapy that is safe and effective for HFREF patients at high risk for atrial fibrillation.”

AF is considered an epidemic cardiovascular disease with an estimated prevalence of at least 2.7 million Americans in 2010. The approved therapies for the treatment or prevention of AF have certain disadvantages in HFREF patients, such as toxic or cardiovascular adverse effects, and most of the approved drugs for AF are contra-indicated or have warnings in their prescribing information for such patients. ARCA believes there is an unmet medical need for new AF treatments that have fewer side effects than currently available therapies and are more effective, particularly in HFREF patients.

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with the Laboratory Corporation of America (LabCorp), under which LabCorp has developed a companion genetic test for Gencaro. For more information please visit http://www.arcabiopharma.com.

Safe Harbor Statement

This press release contains “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential for genetic variations to predict individual patient response to Gencaro, Gencaro’s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, the role of AF burden in diagnosis and treatment of atrial fibrillation and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company’s financial resources and whether they will be sufficient to meet the Company’s business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company’s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA’s filings with the SEC, including without limitation the Company’s annual report on Form 10-K for the year ended December 31, 2012, the Company’s Registration Statement on Form S-1 (Registration No. 333-187508), and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements.